Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results

• About About Us Management Team Board of Directors Timeline

• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2

• Science Overview Publications

• Patients Overview Clinical Trials Expanded Access Policy Resources

• Careers Join Us Culture Core Values Testimonials Benefits

• Collaborations Partnering

• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts

• Contact Us

• About Us

• Management Team

• Board of Directors

• Timeline

• Overview

• Hepatitis C Virus

• Respiratory Syncytial Virus

• SARS-CoV-2

• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2

• KIT Inhibition

• STAT6 Inhibition

• MRGPRX2

• Overview

• Publications

• Overview

• Clinical Trials

• Expanded Access Policy

• Resources

• Join Us

• Culture

• Core Values

• Testimonials

• Benefits

• Partnering

• Overview

• Press Releases

• Events & Presentations

• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

• Financials Quartlery Results Annual Reports SEC Filings

• Corporate Responsibility Overview Environmental Social Governance

• Investor Resources Investor FAQs RSS Feed

• 2026 Annual Meeting

• Email Alerts

• Stock Quote & Chart

• Historic Price Lookup

• Investment Calculator

• Analyst Coverage

• Quartlery Results

• Annual Reports

• SEC Filings

• Overview

• Environmental

• Social

• Governance

• Investor FAQs

• RSS Feed

• Print Page Print Page

• Email Alerts Email Alerts

• RSS Feeds RSS Feeds

• Contact IR Contact IR